Chikungunya Fever Market Research Report Information By Diagnosis (ELISA Based Assays, Serological Tests, Virological Tests), Treatment (Allopathy, Homeopathy), End User (Hospitals And Clinics, Academic Institutes, Research Laboratories) - Global Forecast till 2030

Chikungunya Fever Market Scenario:

The Chikungunya Fever Market is expected to reach USD 483.4 Million by 2030 at 7.6% CAGR during the forecast period 2022-2030.Chikungunya is a mosquito borne viral disease caused by the RNA virus belonging to the alphavirus genus of family Togaviridae. Chikungunya fever has been reported in more than 60 countries of Asia, Africa, Europe and the Americas. Its transmission from human to human is facilitated by the bites of infected female mosquitoes. Most commonly, the mosquitoes involved are Aedes aegypti and Aedes albopictus. Currently, there is no cure for the disease and the treatments are focussed only to relieve the symptoms. In 2019, according to the World Health Organisation, 349 936 suspected and 146 914 laboratory confirmed cases of chikungunya were reported to the PAHO regional office. Countries that reported the most cases were Brazil (265 000 suspected cases), Bolivia and Colombia (19 000 suspected cases, respectively).

Increasing per capita healthcare expenditures, rising R&D investments by the market players, and growing geriatric population are the major factors that will drive the Chikungunya Fever Market growth during the forecasted period. Moreover, pouring government investments and favourable policies will fuel the market. However, factors such as lack of awareness and cost of treatment and diagnosis can restrain the Chikungunya Fever Market growth during the forecasted period.

Intended Audience

• Pharmaceutical companies


• Biotechnological institutes


• Government and Private Laboratories


• Research and Development (R&D) Companies


• Medical Research Laboratories


• Market Research and Consulting Service Providers

by Region

Sources: WHO, annual reports, press release, white paper, and company presentation 

Segmentation

The chikungunya fever market is segmented on the basis of diagnosis, treatment, and end-users.

On the basis of diagnosis, the market is segmented into ELISA based assays, serological tests, virological tests, and others. ELISA based assays is future segmented into IgM based ELISA and IgG ELISA.

On the basis of treatment, the Chikungunya Fever Market is segmented into allopathy, homeopathy, Ayurveda, and others. The allopathy segmented is sub segmented into anti-pyretics, optimal analgesics, and others. The homeopathy segment is sub segmented into pyroginum, rhus-tox, cedron, and others. The ayurveda segment is sub segmented into amrutharista, mahasudarshana churna, dhanvantaram gutika and others.

On the basis of end users, the market is segmented into hospitals and clinics, academic institutes, research laboratories, and others.

Regional Analysis

The Americas dominate the chikungunya fever market owing to a well-developed healthcare sector. Apart from this, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in the Americas. Additionally, increasing geriatric population, rising awareness among the people and expanding R&D expenses for the treatment of chikungunya is boosting the market growth. 

Europe holds the second largest Chikungunya Fever Market, which is followed by Asia Pacific. Availability of funds for research, rising patient population and government support for research & development will drive the market. On 22 September 2019, according to the European Centre for Disease Prevention and Control there were about 102 autochthonous chikungunya cases in Italy. Such trends for chikungunya fever was seen across the region. This is expected to boost the market growth during the forecasted period.

According to the World Health Organisation, the major outbreaks of chikungunya fever are seen in Asia and the Indian subcontinent. This made Asia Pacific the fastest growing region for the market due to the presence of a huge patient population and presence of huge opportunity in the market. Moreover, continuously developing economies like India and China within the region have increasing healthcare expenditures which fuels the Chikungunya Fever Marketgrowth.

On the other hand, the Middle East & Africa has the least share in the Chikungunya Fever Market due to the presence of poor economy especially in the African region. A majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. Research Methodology

Sources: WHO, annual reports, press release, white paper, and company presentation 

Key players for chikungunya fever market

The key players for the chikungunya market are Quest Diagnostics Incorporated. (U.S.A), Alere. (U.S.A), Genome Diagnostics Pvt. Ltd. (India), altona Diagnostics (Europe), Bio-Rad Laboratories, Inc. (U.S.A), Sanat Products Ltd. (India), Taj Pharmaceuticals Limited. (India), and Etubics Corporation (U.S.A).